Skip to content

Discovery pipeline‚Äč

Working in close collaboration with our clinical and industry partners we have discovered biomarker signatures in several disease areas.

Indication
Clinical question
Technology
Tissue
#patients
Outcome
Sezary
Syndrome (CTCL)
Diagnosis of CTCL
CyTOF
PBMCs
66
0.98 AUC patent-pending
Flow-cytometry antibody panel prototype
Endometriosis
Diagnosis of endometriosis
scRNA-seq
OBMCs Endometrium
42
0.9 AUC patent-pending
Clinical validation
Head and Neck Cancer
Prediction of radiotoxicity
CyTOF
PBMCs
30
Initial discovery
Covid19 / ARDS
Prediction of ARDS development in Covid19-parients
CyTOF
PBMCs
Clinical data
37
0.95 – 1 AUC patent-pending
Non-Small Cell Lung Cancer (NSCLC)
Prediction of immunotherapy response
scRNA-seq
PBMCs
27
0.9 – 1.0 AUC In development patent-pending
CAR-T Cells
Prediction of therapy response and toxicity
scRNA-seq
Infusion cell product
23
0.8 AUC efficacy prediction
1 AUC toxicity prediction
Helping you speed up your therapy development and increase your success rate